Taner Şen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Taner Şen has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Mevlüt Demir
Faculty of Medicine, Department of Cardiology, Kütahya Health Sciences University, Kütahya, Turkey
4 shared publications - Mehmet Özgeyik
Ministry of Health Eskisehir City Hospital Eskişehir Turkey
3 shared publications - Onur Dalgıç
Department of Cardiology, Kardiya Medical Center, Izmir, Turkey
3 shared publications - Umut Kocabaş
Department of Cardiology Baskent University Izmir Hospital Izmir Turkey
3 shared publications - Ahmet Dal
Faculty of Medicine, Department of Cardiology, Izmir University of Economics, Izmir, Turkey
2 shared publications - Arda Güler
Department of Cardiology, University of Health Sciences, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Center, Training and Research Hospital, İstanbul, Türkiye
2 shared publications
Latest Publications
- Open Access
- 3 March 2026
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 13 (2)
Bridging heart failure clinic–based guideline-directed medical therapy optimization and real-world practice in heart failure with reduced ejection fraction (HFrEF)
- 3 March 2026
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 13 (2)
Open AccessBridging heart failure clinic–based guideline-directed medical therapy optimization and real-world practice in heart failure with reduced ejection fraction (HFrEF)
- Open Access
- 30 April 2025
- Published by Ordu University in ODÜ Tıp Dergisi
- Vol. 12 (1) , 1-6
A case of coronary perforation with graft-covered stent placement
Coronary artery perforation is a rare but potentially fatal complication during percutaneous coronary intervention. In this case, we report a patient with myocardial infarction who experienced coronary perforation during percutaneous coronary intervention and successful application of the graft stent. In our case, coronary rupture occurred as a result of balloon inflation in a small vessel without making sure that the guidewire was in the lumen. Prolonged balloon inflation at the site of coronary perforation may provide a solution in some cases. In our case, the balloon was inflated proximal to the rupture, the bleeding was stopped by waiting, and the coronary rupture was successfully closed with a graft stent. The balloon or stent balloon should not be inflated without making sure that the coronary lumen is in place. If inflated without being sure, coronary rupture may occur. Steps to manage this complication include rapid closure of the perforated area, administration of protamine sulfate, graft covered stenting and emergency surgery if necessary.
- 30 April 2025
- Published by Ordu University in ODÜ Tıp Dergisi
- Vol. 12 (1) , 1-6
Open AccessA case of coronary perforation with graft-covered stent placement
Coronary artery perforation is a rare but potentially fatal complication during percutaneous coronary intervention. In this case, we report a patient with myocardial infarction who experienced coronary perforation during percutaneous coronary intervention and successful application of the graft stent. In our case, coronary rupture occurred as a result of balloon inflation in a small vessel without making sure that the guidewire was in the lumen. Prolonged balloon inflation at the site of coronary perforation may provide a solution in some cases. In our case, the balloon was inflated proximal to the rupture, the bleeding was stopped by waiting, and the coronary rupture was successfully closed with a graft stent. The balloon or stent balloon should not be inflated without making sure that the coronary lumen is in place. If inflated without being sure, coronary rupture may occur. Steps to manage this complication include rapid closure of the perforated area, administration of protamine sulfate, graft covered stenting and emergency surgery if necessary.
- Open Access
- 27 January 2025
- Published by Wiley in Clinical Cardiology
- Vol. 48 (1) , e70088
Incidence and Predictors of Clinical Outcomes in Real‐Life Patients With Atrial Fibrillation Treated With Oral Factor Xa Inhibitors: The Follow‐Up Results of the ANATOLIA‐AF Study
Objective: The main objective of this study is to determine the incidence and predictors of clinical outcomes in patients with AF treated with factor Xa inhibitors in a real‐world setting.Methods: The present study was a multicentre and observational study that included patients with AF who were treated with factor Xa inhibitors. The primary outcome was the composite of ischemic stroke, TIA, systemic embolism, major bleeding, and all‐cause mortality.Results: A total of 1162 patients from 26 cardiology centers were included in this study, with a median age of 72 years. During the median 12‐month follow‐up period, the primary outcome occurred in 195 patients (16.8%). Treatment with rivaroxaban compared with apixaban and edoxaban showed a lower rate of ischemic stroke, TIA, and/or systemic embolism (2.2% vs. 4.7% vs. 6.5%, respectively, p = 0.014). The major bleeding rate was similar between all three factor Xa inhibitors. The all‐cause mortality rate in the rivaroxaban group was lower compared with the apixaban and edoxaban groups (9.8% vs. 15.1% vs. 12.4%, respectively, p = 0.042). Overall, the frequency of primary outcome was 13.8%, 19.6%, and 20.6% for patients treated with rivaroxaban, apixaban, and edoxaban, respectively (p = 0.019). Older age, male sex, low body weight, high bleeding risk, heart failure, hypertension, liver failure, and treatment with apixaban 2.5 mg b.i.d. were independently associated with the development of primary outcome.Conclusion: The follow‐up data from the ANATOLIA‐AF study provides detailed data about the incidence and independent predictors of adverse clinical outcomes in patients with AF treated with factor Xa inhibitor treatment.
- 27 January 2025
- Published by Wiley in Clinical Cardiology
- Vol. 48 (1) , e70088
Open AccessIncidence and Predictors of Clinical Outcomes in Real‐Life Patients With Atrial Fibrillation Treated With Oral Factor Xa Inhibitors: The Follow‐Up Results of the ANATOLIA‐AF Study
Objective: The main objective of this study is to determine the incidence and predictors of clinical outcomes in patients with AF treated with factor Xa inhibitors in a real‐world setting.Methods: The present study was a multicentre and observational study that included patients with AF who were treated with factor Xa inhibitors. The primary outcome was the composite of ischemic stroke, TIA, systemic embolism, major bleeding, and all‐cause mortality.Results: A total of 1162 patients from 26 cardiology centers were included in this study, with a median age of 72 years. During the median 12‐month follow‐up period, the primary outcome occurred in 195 patients (16.8%). Treatment with rivaroxaban compared with apixaban and edoxaban showed a lower rate of ischemic stroke, TIA, and/or systemic embolism (2.2% vs. 4.7% vs. 6.5%, respectively, p = 0.014). The major bleeding rate was similar between all three factor Xa inhibitors. The all‐cause mortality rate in the rivaroxaban group was lower compared with the apixaban and edoxaban groups (9.8% vs. 15.1% vs. 12.4%, respectively, p = 0.042). Overall, the frequency of primary outcome was 13.8%, 19.6%, and 20.6% for patients treated with rivaroxaban, apixaban, and edoxaban, respectively (p = 0.019). Older age, male sex, low body weight, high bleeding risk, heart failure, hypertension, liver failure, and treatment with apixaban 2.5 mg b.i.d. were independently associated with the development of primary outcome.Conclusion: The follow‐up data from the ANATOLIA‐AF study provides detailed data about the incidence and independent predictors of adverse clinical outcomes in patients with AF treated with factor Xa inhibitor treatment.
- Open Access
- 23 January 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 124 (5) , 479-480
Statins alone are not enough: The need to add a second low-density lipoprotein cholesterol-lowering drug to achieve guideline targets
- 23 January 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 124 (5) , 479-480
Open AccessStatins alone are not enough: The need to add a second low-density lipoprotein cholesterol-lowering drug to achieve guideline targets
- Open Access
- 1 January 2025
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 29 (2) , 106-107
Reply to Letter to the Editor: “Current Guidelines Should be Taken into Consideration in the Management of Dyslipidemia”
- 1 January 2025
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 29 (2) , 106-107
Open AccessReply to Letter to the Editor: “Current Guidelines Should be Taken into Consideration in the Management of Dyslipidemia”
- Open Access
- 1 January 2024
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 28 (6) , 273-282
Adherence to Current Dyslipidemia Guideline in Patients Utilizing Statins According to Risk Groups and Gender Differences: The AIZANOI Study
The aim of this study was to assess the adherence to the current European Society of Cardiology dyslipidemia guidelines, the ratio of reaching target values according to risk groups, and the reasons for not reaching LDL-cholesterol (LDL-C) goals in patients on already statin therapy in a cardiology outpatient population. The AIZANOI study is a multi-center, cross-sectional observational study including conducted in 9 cardiology centers between August 1, 2021, and November 1, 2021. A total of 1225 patients (mean age 62 ± 11 years, 366 female) who were already on statin therapy for at least 3 months were included. More than half (58.2%) of the patients were using high-intensity statin regimens. Only 26.2% of patients had target LDL-C level according to their risk score. Despite 58.4% of very high-risk patients and 44.4% of high-risk patients have been using a high-intensity statin regimen, only 24.5% of very-high-risk patients and only 34.9% of high-risk patients have reached guideline-recommended LDL-C levels. Most prevalent reason for not using target dose statin was physician preference (physician inertia) (40.3%). The AIZANOI study showed that we achieved a target LDL-C level in only 26.2% of patients using statin therapy. Although 58.4% of patients with a very high SCORE risk and 44.4% of patients with a high SCORE risk were using a target dose statin regimen, we were only able to achieve guideline-recommended LDL-C levels in 24.5% and 34.9% of them, respectively, in cardiology outpatients clinics. Physician inertia is one of the major factors in non-adherence to guidelines. These findings highlight that combination therapy is needed in most of the patients.
- 1 January 2024
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 28 (6) , 273-282
Open AccessAdherence to Current Dyslipidemia Guideline in Patients Utilizing Statins According to Risk Groups and Gender Differences: The AIZANOI Study
The aim of this study was to assess the adherence to the current European Society of Cardiology dyslipidemia guidelines, the ratio of reaching target values according to risk groups, and the reasons for not reaching LDL-cholesterol (LDL-C) goals in patients on already statin therapy in a cardiology outpatient population. The AIZANOI study is a multi-center, cross-sectional observational study including conducted in 9 cardiology centers between August 1, 2021, and November 1, 2021. A total of 1225 patients (mean age 62 ± 11 years, 366 female) who were already on statin therapy for at least 3 months were included. More than half (58.2%) of the patients were using high-intensity statin regimens. Only 26.2% of patients had target LDL-C level according to their risk score. Despite 58.4% of very high-risk patients and 44.4% of high-risk patients have been using a high-intensity statin regimen, only 24.5% of very-high-risk patients and only 34.9% of high-risk patients have reached guideline-recommended LDL-C levels. Most prevalent reason for not using target dose statin was physician preference (physician inertia) (40.3%). The AIZANOI study showed that we achieved a target LDL-C level in only 26.2% of patients using statin therapy. Although 58.4% of patients with a very high SCORE risk and 44.4% of patients with a high SCORE risk were using a target dose statin regimen, we were only able to achieve guideline-recommended LDL-C levels in 24.5% and 34.9% of them, respectively, in cardiology outpatients clinics. Physician inertia is one of the major factors in non-adherence to guidelines. These findings highlight that combination therapy is needed in most of the patients.
- 1 December 2023
- Published by Galenos Yayinevi in International Journal of the Cardiovascular Academy
- Vol. 9 (4) , 95-98
Successful Retrieval of Stripped Coronary Stents Using the Twisted Guide Wire Technique
- 1 December 2023
- Published by Galenos Yayinevi in International Journal of the Cardiovascular Academy
- Vol. 9 (4) , 95-98
Successful Retrieval of Stripped Coronary Stents Using the Twisted Guide Wire Technique
- Open Access
- 1 January 2023
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 27 (11) , 628-638
The Definition of Sarcomeric and Non-Sarcomeric Gene Mutations in Hypertrophic Cardiomyopathy Patients: A Multicenter Diagnostic Study Across Türkiye
Hypertrophic cardiomyopathy is a common genetic heart disease and up to 40%-60% of patients have mutations in cardiac sarcomere protein genes. This genetic diagnosis study aimed to detect pathogenic or likely pathogenic sarcomeric and non-sarcomeric gene mutations and to confirm a final molecular diagnosis in patients diagnosed with hypertrophic cardiomyopathy. A total of 392 patients with hypertrophic cardiomyopathy were included in this nationwide multicenter study conducted at 23 centers across Türkiye. All samples were analyzed with a 17-gene hypertrophic cardiomyopathy panel using next-generation sequencing technology. The gene panel includes ACTC1, DES, FLNC, GLA, LAMP2, MYBPC3, MYH7, MYL2, MYL3, PLN, PRKAG2, PTPN11, TNNC1, TNNI3, TNNT2, TPM1, and TTR genes. The next-generation sequencing panel identified positive genetic variants (variants of unknown significance, likely pathogenic or pathogenic) in 12 genes for 121 of 392 samples, including sarcomeric gene mutations in 30.4% (119/392) of samples tested, galactosidase alpha variants in 0.5% (2/392) of samples and TTR variant in 0.025% (1/392). The likely pathogenic or pathogenic variants identified in 69 (57.0%) of 121 positive samples yielded a confirmed molecular diagnosis. The diagnostic yield was 17.1% (15.8% for hypertrophic cardiomyopathy variants) for hypertrophic cardiomyopathy and hypertrophic cardiomyopathy phenocopies and 0.5% for Fabry disease. Our study showed that the distribution of genetic mutations, the prevalence of Fabry disease, and TTR amyloidosis in the Turkish population diagnosed with hypertrophic cardiomyopathy were similar to the other populations, but the percentage of sarcomeric gene mutations was slightly lower.
- 1 January 2023
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 27 (11) , 628-638
Open AccessThe Definition of Sarcomeric and Non-Sarcomeric Gene Mutations in Hypertrophic Cardiomyopathy Patients: A Multicenter Diagnostic Study Across Türkiye
Hypertrophic cardiomyopathy is a common genetic heart disease and up to 40%-60% of patients have mutations in cardiac sarcomere protein genes. This genetic diagnosis study aimed to detect pathogenic or likely pathogenic sarcomeric and non-sarcomeric gene mutations and to confirm a final molecular diagnosis in patients diagnosed with hypertrophic cardiomyopathy. A total of 392 patients with hypertrophic cardiomyopathy were included in this nationwide multicenter study conducted at 23 centers across Türkiye. All samples were analyzed with a 17-gene hypertrophic cardiomyopathy panel using next-generation sequencing technology. The gene panel includes ACTC1, DES, FLNC, GLA, LAMP2, MYBPC3, MYH7, MYL2, MYL3, PLN, PRKAG2, PTPN11, TNNC1, TNNI3, TNNT2, TPM1, and TTR genes. The next-generation sequencing panel identified positive genetic variants (variants of unknown significance, likely pathogenic or pathogenic) in 12 genes for 121 of 392 samples, including sarcomeric gene mutations in 30.4% (119/392) of samples tested, galactosidase alpha variants in 0.5% (2/392) of samples and TTR variant in 0.025% (1/392). The likely pathogenic or pathogenic variants identified in 69 (57.0%) of 121 positive samples yielded a confirmed molecular diagnosis. The diagnostic yield was 17.1% (15.8% for hypertrophic cardiomyopathy variants) for hypertrophic cardiomyopathy and hypertrophic cardiomyopathy phenocopies and 0.5% for Fabry disease. Our study showed that the distribution of genetic mutations, the prevalence of Fabry disease, and TTR amyloidosis in the Turkish population diagnosed with hypertrophic cardiomyopathy were similar to the other populations, but the percentage of sarcomeric gene mutations was slightly lower.
- Open Access
- 1 January 2023
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 27 (5) , E15-E16
Giant Coronary Artery Aneurysm with a Thrombus
- 1 January 2023
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 27 (5) , E15-E16
Open AccessGiant Coronary Artery Aneurysm with a Thrombus
- 17 December 2022
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 38 (3) , 581-599
PrevAleNce and Associated factors of inappropriaTe dosing of direct Oral anticoaguLants In pAtients with Atrial Fibrillation: the ANATOLIA-AF Study
Purpose Inappropriate dosing of direct oral anticoagulants is associated with an increased risk of stroke, systemic embolism, major bleeding, cardiovascular hospitalization, and death in patients with atrial fibrillation. The main goal of the study was to determine the prevalence and associated factors of inappropriate dosing of direct oral anticoagulants in real-life settings. Methods This study was a multicenter, cross-sectional, observational study that included 2004 patients with atrial fibrillation. The study population was recruited from 41 cardiology outpatient clinics between January and May 2021. The main criteria for inappropriate direct oral anticoagulant dosing were defined according to the recommendations of the European Heart Rhythm Association. Results The median age of the study population was 72 years and 58% were women. Nine-hundred and eighty-seven patients were prescribed rivaroxaban, 658 apixaban, 239 edoxaban, and 120 dabigatran. A total of 498 patients (24.9%) did not receive the appropriate dose of direct oral anticoagulants. In a logistic regression model, advanced age, presence of chronic kidney disease and permanent atrial fibrillation, prescription of reduced doses of direct oral anticoagulants or edoxaban treatment, concomitant use of amiodarone treatment, and non-use of statin treatment were significantly associated with potentially inappropriate dosing of direct oral anticoagulants. Conclusion The study demonstrated that the prevalence of inappropriate direct oral anticoagulant dosing according to the European Heart Rhythm Association recommendations was 24.9% in patients with atrial fibrillation. Several demographic and clinical factors were associated with the inappropriate prescription of direct oral anticoagulants.
- 17 December 2022
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 38 (3) , 581-599
PrevAleNce and Associated factors of inappropriaTe dosing of direct Oral anticoaguLants In pAtients with Atrial Fibrillation: the ANATOLIA-AF Study
Purpose Inappropriate dosing of direct oral anticoagulants is associated with an increased risk of stroke, systemic embolism, major bleeding, cardiovascular hospitalization, and death in patients with atrial fibrillation. The main goal of the study was to determine the prevalence and associated factors of inappropriate dosing of direct oral anticoagulants in real-life settings. Methods This study was a multicenter, cross-sectional, observational study that included 2004 patients with atrial fibrillation. The study population was recruited from 41 cardiology outpatient clinics between January and May 2021. The main criteria for inappropriate direct oral anticoagulant dosing were defined according to the recommendations of the European Heart Rhythm Association. Results The median age of the study population was 72 years and 58% were women. Nine-hundred and eighty-seven patients were prescribed rivaroxaban, 658 apixaban, 239 edoxaban, and 120 dabigatran. A total of 498 patients (24.9%) did not receive the appropriate dose of direct oral anticoagulants. In a logistic regression model, advanced age, presence of chronic kidney disease and permanent atrial fibrillation, prescription of reduced doses of direct oral anticoagulants or edoxaban treatment, concomitant use of amiodarone treatment, and non-use of statin treatment were significantly associated with potentially inappropriate dosing of direct oral anticoagulants. Conclusion The study demonstrated that the prevalence of inappropriate direct oral anticoagulant dosing according to the European Heart Rhythm Association recommendations was 24.9% in patients with atrial fibrillation. Several demographic and clinical factors were associated with the inappropriate prescription of direct oral anticoagulants.